VBI Vaccines Shows Promise in Glioblastoma Trial

VBI Vaccines (VBIV) has released an update.

VBI Vaccines has reported promising interim results from their Phase 2b trial of VBI-1901, an immunotherapeutic cancer vaccine for recurrent glioblastoma, showing a 43% disease control rate compared to 0% in the control group. The vaccine has been granted Fast Track and Orphan Drug Designations by the FDA, with one patient achieving a 67% tumor reduction. Additional data, including survival rates, are expected by the end of 2024, potentially leading to accelerated development and approval discussions.

For further insights into VBIV stock, check out TipRanks’ Stock Analysis page.